Background/Aims: Chronic kidney disease-mineral bone disorder is a major complication affecting the vast majority of chronic kidney disease patients. A hallmark of the disorder is an altered parathyroid gland biology resulting in secondary hyperparathyroidism. This condition is widely treated by calcimimetics like cinacalcet which act by allosteric activation of the calcium sensing receptor. Methods: Here, we present a linear multi-compartment model based on physiological principles such as first-pass metabolism and protein binding, which captures all relevant pharmacokinetic parameters of cinacalcet. Results: Due to the linear structure of the model, simulations are numerically stable and allow fast and accurate short or long-term predictions of cinacalcet concentrations in the body. Conclusion: The model compartments are physiological meaningful and can be easily adjusted to various conditions like impaired hepatic clearance or different drug administration regimens. Moreover, the model can be easily adapted to specific patient groups.
Introduction
Blood ionized calcium concentrations (Ca 2+ ) have to be maintained within a very narrow range of around 2%; a deviation from this range will result in serious health issues and if persistent in life threatening situations [1] . A key endocrine regulator for Ca 2+ is the parathyroid hormone (PTH) [2] [3] [4] . PTH stimulates bone remodeling thereby ensuring a net release of calcium from the bone storage. Furthermore, it stimulates vitamin D conversion to its metabolic active form 1, 25-dihydroxyvitamin D3, and it inhibits renal phosphate reabsorption while enhancing renal calcium reabsorption. The key regulator for the detection of changes in blood ionized calcium levels and the subsequent secretion of PTH is the calcium-sensing receptor (CaSR) on the surface of parathyroid gland (PTG) cells [5] [6] [7] . If activated by calcium binding, the CaSR down-regulates PTH production and secretion as well as cell proliferation of PTG cells.
In patients suffering from chronic kidney disease (CKD) the impairment of vitamin D metabolism as well as the impaired clearance of PTH and phosphate by the kidneys trigger a cascade of feedback loops resulting eventually in chronic kidney disease-mineral bone disorder (CKD-MBD). CKD-MBD is a complex disorder affecting the vast majority of chronic kidney disease patients. It is associated with a variety of pathological effects like renal osteodystrophy [8] [9] [10] or vascular calcification and an increased risk for cardiovascular events, the leading cause of mortality in CKD patients [11] [12] [13] [14] . A hallmark of CKD-MBD is secondary hyperparathyroidism, reduced expression of calcium-sensing receptor and parathyroid gland cell hyperplasia [15] [16] [17] [18] .
The 2017 KDIGO CKD-MBD Guideline Update suggests maintaining intact PTH levels in the range of approximately 2 to 9 times the upper normal limit for the assay [19] . One strategy to reach this goal is to target the CaSR. Calcimimetic drugs like cinacalcet or etelcalcetide enhance the interaction between the ionized calcium concentration (Ca 2+ ) and the CaSR by allosteric activation [20] . The higher sensitivity of the CaSR to Ca 2+ leads to an inverse relationship between plasma PTH and cinacalcet concentrations. PTH concentration declines after the administration of cinacalcet until it reaches a minimum approximately 2-3 hours after dosing.
Cinacalcet hydrochlorid, which was approved by the FDA in 2004, is widely used in hemodialysis patients [21] and has been listed under the 100 best selling pharmaceuticals world wide in the last years. In addition to secondary hyperparathyroidism in patients with CKD on dialysis, cinacalcet is also approved for the treatment of hypercalcemia in patients with parathyroid carcinoma, and severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy. Its pharmacokinetics are well established in clinical studies [20, [22] [23] [24] [25] [26] . Following oral administration the plasma concentration peaks within 2-6 hours. The absolute bio-availability is only between 20-25% while absorption is close to 100% indicating a high first-pass metabolism. Since almost 95% of the drug in the plasma is protein bound, the affect of hemodialysis on the pharmacokinetics of the drug can be neglected [25] .
The mechanisms leading to CKD-MBD are many and highly complex. Thus, a multitude of mathematical models were established in order to gain a better understanding of the multidimensional factors controlling the PTH household [27] [28] [29] or PTH and bone remodeling [30] . For clinical application any proposed model should be able to predict the state of individual patients and ideally indicate an optimal treatment strategy. Due to the vast clinical use of cinacalcet, a realistic model of CKD-MBD has to feature the use of cinacalcet and its effects. To be of clinical use the cinacalcet model should be readily adaptable to various conditions, such as hepatic impairment enhancing cinacalcet exposure [31] . Moreover, it should be able to reflect different administration scenarios including patient adherence which is known to be poor, due to gastrointestinal side effects and a general high pill load in this patient group [32] .
Therefore, the aim of this study was to build a multi-compartment model based on physiological considerations capturing all major pharmacokinetics parameters of cinacalcet. Moreover, the model should allow an intuitive individualization to various conditions or administration regimens and omit any numerical instabilities in order to be easily combined with or incorporated to other physiological models.
Materials and Methods

Pharmacokinetics
The low bio-availability of 20 [32] . Around 95% of the drug is protein bound.
Therefore, the effect of hemodialysis on the pharmacokinetics is negligible [26] . The high volume of distribution at steady state of 1000 liters indicates a vast distribution outside the systemic circulation [33] . Experiments with radioactive labeled cinacalcet have shown that the drug peaks at different times in different tissues. Roughly, tissue can be lumped into two groups: one group with short time to peak and one group with longer time to peak operating like a buffer for cinacalcet [33] .
Mathematical model
The proposed model is depicted in Fig. 1 . We use six physiological motivated compartments, i.e.
compartments for absorption, first pass metabolism, plasma free drug and protein bound as well as two tissue compartments. It is notable that the tissue compartment with the longer time to peak can be omitted in most situations reducing the system to 5 compartments. The impact of the sixth compartment on the predictions based the parameter set presented in this manuscript is marginal. However, the tissue compartment with longer time to peak includes adipose tissue and adrenals [33] . Therefore, the six compartment model will be useful when addressing patients deviating from the norm regarding adipose tissue or adrenal gland mass.
We use constant rate functions between the compartments. The amount of drug in each compartment can be calculated by solving the following system of linear ordinary differential equations: V which is defined as should be around 1000 L [25, 33] . Finally, the bio-availability Bio should be between 20 and 25% for fastening patients. We calculate the bio availability as where iv C is the plasma concentration of the intravenously administered drug. We calculate iv C by analyzing the model modified for intravenous bolus injection. The drug is administered to the "Plasma free drug" compartment thereby omitting the absorption and first pass metabolism compartments. oral C is the plasma concentration of the orally administered drug [25] .
Model parameters and sensitivity analysis
Typical model parameters are given in Table 1 With the parameters set presented in Table 1 the difference between the exact value and the approximated value is less then 0.01%. The reduction of P l k by 53% enhances the terminal half-life 1.4 fold and the AUC ∞ 2.2-fold, the reduction of P l k by 76% enhances the terminal half-life 1.8 fold and the AUC ∞ 4.2-fold.
Another example would be the administration with food. It has been shown that the administration of a single dose of 90mg cinacalcet with high fat and low fat meal enhances the bio-availability significantly resulting in increase of AUC ∞ of 68% (90% confidence interval: 48% to 89%) and 50% (90% confidence interval: 33% to 70%), respectively [25] . Mean max t is higher in fastening subjects (6h) then in subjects receiving cinacalcet with a high fat diet (4h) and a low fat diet (3.5h). Terminal half-life was comparable between the administration schemes. Since bio-availability is associated with absorption and first-pass 
Results
Main pharmacokinetics profiles
The simulated pharmacokinetics profile of a single oral administration based on the proposed six-compartment model is shown in Fig. 2 and Fig. 3 . The results are qualitatively and quantitatively in close agreement with published clinical data. The simulations of daily administration of cinacalcet predict a steady state within seven days (Fig. 4) which is similar to clinically observed behavior of the drug [33] .
Different dosing regimens
To assess the impact of dosing regimens on the total exposure we modeled the weekly average cinacalcet concentration in the blood for three different dosing regimens: daily administration, administration three times a week, and administration with a realistic medication refill rate of 64% [34] . For the realistic medication refill rate scenario we chose days without administration randomly (Fig. 5) .
Discussion
The linear multi-compartment model introduced in this article is used to describe the complex pharmacokinetic behavior of cinacalcet in the human body. This approach allows the analysis of the effect of different dosing regimens on the drug concentration in the body that could otherwise only be addressed by clinical studies. The analysis can help to evaluate dose titration and administration schemes. Calcium homeostasis in the human body is achieved by a complex network of regulators, one of them being the kidney. If the kidney function starts to decline, a cascade of physiological processes eventually result in secondary hyperparathyroidism. Due to the complexity of the system, a growing number of mathematical models have been published with the aim to analyze the driving factors of calcium homeostasis, secondary hyperparathyroidism, and CKD-MBD [27, 29, 30, [35] [36] [37] [38] . However these models did not include a detailed model of cinacalcet, a drug widely prescribed in patients with secondary hyperparathyroidism. Our pharmacokinetic model can be easily incorporated in all other models by using an operational model of allosterism which transfers the actual Ca 2+ concentration by the amount of free drug in the plasma [39] [40] [41] .
It is worth noticing that many model approaches with more than one compartment are able to predict one or two pharmacokinetics parameter within a desired range. The model introduced in this article is minimal in the sense that a linear mass-balance model with less than five compartments is not able to capture all seven key pharmacokinetic parameters (i. 
Conclusion
In conclusion, we have developed a mathematical model incorporating key components of cinacalcet pharmacokinetics. A great advantage of this model is its linear structure allowing long term predictions which are fast and numerically stable. The model is a general compartment model which could be used to evaluate different drugs. An example would be etelcalcetide, another calcimimetic which is administered intravenously [42] . In this case the model reduces to a four compartment model since the intestinal absorption and first-pass metabolism compartments are obsolete. Due to the physiological meaningful compartments, adjustments to conditions like hepatic impairment are straight forward. Combined with a model for the parathyroid gland and bone metabolism it provides a ready to use tool for clinical trial simulations to explore effects of relevant factors, such as patient adherence, off-label administration regimens, or the effect of administration combined with food intake.
